Captix Biomedical Pty Ltd is a pioneering Australian company developing innovative, implantable, medical technologies to optimise the therapeutic outcomes of cell therapies. Captixbio’s IMITA® device is a cell protection and delivery technology intended to transform the current cell therapy paradigm for the treatment of Type 1 diabetes. Our team is dedicated to transforming the lives of people living with Type 1 diabetes around the world.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2018
Main Therapeutic Focus:
Immunology
Lead Product in Development:
IMITA
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
